Next Article in Journal
Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
Previous Article in Journal
A New Phenylpyrazoleanilide, Y-320, Inhibits Interleukin 17 Production and Ameliorates Collagen-Induced Arthritis in Mice and Cynomolgus Monkeys
Previous Article in Special Issue
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics
Pharmaceuticals 2014, 7(1), 18-28; doi:10.3390/ph7010018
Review

Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

1,†
, 2,†
 and 2,*
Received: 18 October 2013; in revised form: 16 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013
(This article belongs to the Special Issue Immunosuppressant Drugs)
View Full-Text   |   Download PDF [191 KB, updated 31 December 2013; original version uploaded 30 December 2013]
Abstract: Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.
Keywords: autoimmune liver disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; overlap syndrome autoimmune liver disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; overlap syndrome
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Abhyankar, A.; Tapper, E.; Bonder, A. Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. Pharmaceuticals 2014, 7, 18-28.

AMA Style

Abhyankar A, Tapper E, Bonder A. Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. Pharmaceuticals. 2014; 7(1):18-28.

Chicago/Turabian Style

Abhyankar, Anita; Tapper, Elliot; Bonder, Alan. 2014. "Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient." Pharmaceuticals 7, no. 1: 18-28.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert